Abraham (Avri) Rubinstein is a Professor Emeritus of Pharmaceutical Sciences at The Hebrew University of Jerusalem, Faculty of Medicine, School of Pharmacy Institute for Drug Research. After completing his M.Sc. degree (physical pharmacy) he joined the R&D division of Teva Pharmaceutical Industries, at which place he was promoted to head the Pharmacy R&D laboratory of the company. After 8 years in the industry he returned to the Hebrew University to complete his graduate studies (physical pharmacy and pharmacokinetics), spent two years as a postdoctoral fellow in the University of Wisconsin-Madison (GI physiology, motility and oral drug delivery) and joined the School of Pharmacy in Jerusalem as a faculty member. Apart of being a faculty member at the Hebrew University, Prof. Rubinstein was also an Adjunct Professor at the Rutgers School of Pharmacy, N.J., a member of the Board of Scientific Advisors of the Controlled Release Society of Bioactive Materials (CRS) and the President and a Founder of the Israeli Chapter of the Society (ICRS).
Professor Rubinstein is the author of more than 110 research articles, reviews and book chapters, 130 published presentations and 5 enabled patents. Three of the technologies he developed were purchased by start-up companies. read more
Research Interest
- Drug delivery design
- GI mucosa
- Targeting
- Multi-drug delivery
- Synergism
- Saccharide polymers
- Targetable polymers
- Implants
- Colonic delivery
Recent Publications
- Sharon Gabbay R. and Rubinstein A., Synchronizing the release rates of topotecan and paclitaxel from a self-eroding crosslinked chitosan - PLGA platform. Int J. Pharm., 623: 121945, 2022.
- Generalizing research findings for enhanced reproducibility: an approach based on verbal alternative representations
- Controlling the release rate of topotecan from PLGA spheres and increasing its cytotoxicity towards glioblastoma cells by co-loading with calcium chloride